Comparative Pharmacology
Head-to-head clinical analysis: OPTIRAY 160 versus OPTIRAY 350.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPTIRAY 160 versus OPTIRAY 350.
OPTIRAY 160 vs OPTIRAY 350
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopaque contrast agent that attenuates X-rays, providing enhanced visualization of vascular structures and organs during imaging procedures.
Iodinated radiocontrast agent that attenuates X-rays and enhances visualization of vascular structures and organs during imaging procedures.
Intravenous: 50-150 mL (total dose 8-30 g iodine) as a bolus or rapid infusion; Intra-arterial: Variable per procedure; maximum 250 mL per procedure.
Intravenous administration: 50-150 mL of 350 mgI/mL solution for contrast-enhanced CT; dose determined by procedure, body weight, and clinical indication. Intra-arterial: Varies per procedure, typically 30-60 mL total. Maximum single dose not established; avoid exceeding 5 mL/kg body weight.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 to 2 hours in patients with normal renal function. Prolonged in renal impairment, up to 20–30 hours in severe renal failure.
2.0 ± 0.4 hours in patients with normal renal function (creatinine clearance >90 mL/min); prolonged to 10-40 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal excretion via glomerular filtration; approximately 95% of the administered dose is excreted unchanged in the urine within 24 hours. Fecal excretion is negligible (<1%).
Renal: 90-95% as unchanged drug via glomerular filtration within 24 hours; biliary/fecal: <5%
Category C
Category C
Radiological Contrast Agent
Radiological Contrast Agent